The estimated Net Worth of Lori A Woods is at least $929 millier dollars as of 13 April 2023. Ms. Woods owns over 187,500 units of Perspective Therapeutics Inc stock worth over $512,463 and over the last 17 years she sold ISR stock worth over $0. In addition, she makes $416,524 as Chief Executive Officer et Director at Perspective Therapeutics Inc.
Sign up
Ms. Woods ISR stock SEC Form 4 insiders trading
Lori has made over 10 trades of the Perspective Therapeutics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently she exercised 187,500 units of ISR stock worth $114,375 on 13 April 2023.
The largest trade she's ever made was exercising 262,500 units of Perspective Therapeutics Inc stock on 3 February 2020 worth over $128,625. On average, Lori trades about 67,929 units every 81 days since 2007. As of 13 April 2023 she still owns at least 1,334,538 units of Perspective Therapeutics Inc stock.
You can see the complete history of Ms. Woods stock trades at the bottom of the page.
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!
Lori Woods biography
Lori A. Woods serves as Chief Executive Officer, Director of the Company. Ms. Woods returned to Isoray after previously serving as Vice President from 2006 to February 2008 at which time she was appointed Acting Chief Operating Officer before her appointment to Chief Operating Officer in February 2009, a position she held until January 2010. Beginning in February 2016, and continuing until her appointment as Interim CEO on June 4, 2018, Ms. Woods served as a senior consultant to Isoray. Ms. Woods was appointed CEO of the Company on December 12, 2018. From February 16, 2016 to June 3, 2018, Ms. Woods was a founder of Medvio, LLC, a medical device consulting company focused on the urology and oncology space. During her time at Medvio she worked with large public and international medical device companies, supporting the approval process and distribution of products in diverse international markets. Further, she worked with various partners to develop proprietary technologies for the colorectal and liver treatment markets. Previously from January 2002 to July 2006, Ms. Woods served as Chief Executive Officer of Pro-Qura, Inc., a privately-owned cancer treatment management company focused on the quality delivery of brachytherapy treatments for prostate cancer. She has also served as the Director of Business Development for the Tumor Institute Radiation Oncology Group and the Seattle Prostate Institute (SPI) in Seattle, WA. SPI was an early innovator in prostate brachytherapy treatments and assisted in the training of more than 2,000 physicians in the use of prostate brachytherapy. Ms. Woods served as a board member of the Northwest division of the Juvenile Diabetes Research Foundation, focusing on their digital awareness programs, including their website and SEO strategy, and their public relations efforts. Ms. Woods earned a Bachelor of Science degree in Business Administration - Marketing and Communications from Loma Linda University, CA. Ms. Woods brings to the Board extensive experience and credibility in the
What is the salary of Lori Woods?
As the Chief Executive Officer et Director of Perspective Therapeutics Inc, the total compensation of Lori Woods at Perspective Therapeutics Inc is $416,524. There are no executives at Perspective Therapeutics Inc getting paid more.
How old is Lori Woods?
Lori Woods is 56, she's been the Chief Executive Officer et Director of Perspective Therapeutics Inc since 2018. There are 3 older and 13 younger executives at Perspective Therapeutics Inc. The oldest executive at Perspective Therapeutics Inc is Philip Vitale, 73, who is the Independent Director.
What's Lori Woods's mailing address?
Lori's mailing address filed with the SEC is 350 HILLS STREET, SUITE 106, , RICHLAND, WA, 99354.
Insiders trading at Perspective Therapeutics Inc
Over the last 18 years, insiders at Perspective Therapeutics Inc have traded over $0 worth of Perspective Therapeutics Inc stock and bought 1,651,741 units worth $855,397 . The most active insiders traders include Lori A Woods, Thomas C Lavoy et Dwight William Babcock. On average, Perspective Therapeutics Inc executives and independent directors trade stock every 60 days with the average trade being worth of $14,501. The most recent stock trade was executed by Lori A Woods on 13 April 2023, trading 187,500 units of ISR stock currently worth $114,375.
What does Perspective Therapeutics Inc do?
Isoray, Inc., through its subsidiary, Isoray Medical, Inc., is the sole producer of Cesium Blu brachytherapy seeds, which are expanding brachytherapy treatment options throughout the body.
What does Perspective Therapeutics Inc's logo look like?
Complete history of Ms. Woods stock trades at Perspective Therapeutics Inc
Perspective Therapeutics Inc executives and stock owners
Perspective Therapeutics Inc executives and other stock owners filed with the SEC include:
-
Lori Woods,
Chief Executive Officer, Director -
Lori A. Holmes-Woods,
CEO & Director -
Michael Krachon,
Executive Vice President of Sales and Marketing -
William Cavanagh,
Chief Research and Development Officer -
Michael L. Krachon,
Exec. VP of Sales & Marketing -
Jennifer Streeter,
COO & VP of HR -
William A. Cavanagh III,
Chief R&D Officer -
Krista Cline,
Senior Director of Operations, Corporate Secretary -
Philip Vitale,
Independent Director -
Alan Hoffmann,
Independent Director -
Jonathan Hunt,
Chief Financial Officer, Co-Principal Financial Officer -
Mark Austin,
Controller, Co-Principal Financial and Principal Accounting Officer -
Jennifer Streeter,
Chief Operating Officer, Vice President of Human Resources -
Michael McCormick,
Independent Chairman of the Board -
Krista Cline,
Sr. Director of Operations & Corp. Sec. -
Mark J. Austin CPA,
VP of Fin., Controller, Co-Principal Financial, Principal Accounting Officer & Sec. -
Jonathan R. Hunt,
CFO & Co-Principal Financial Officer -
Frank Morich,
Director -
Brien Ragle,
Controller -
Dwight William Babcock,
CEO -
Matthew Branson,
Principal Fin & Acct Officer -
Robert F Iii Williamson,
Director -
Thomas C Lavoy,
Director -
Albert Louis Smith,
Director -
Roger Girard,
CEO/President -
Robert R Kauffman,
Director -
Fredric Swindler,
Vice President -
David Swanberg,
EVP Operations & Secretary -
Stephen Boatwright,
Director